Decade-long study raises new questions about antibiotic use for cystic fibrosis

March 26, 2012
John J. LiPuma, M.D., of the University of Michigan Health System, was the senior author of a decade-long cystic fibrosis study that found aggressive use of antibiotics to treat cystic fibrosis may not always be the best answer. Credit: University of Michigan Health System

When it comes to treating cystic fibrosis, the current standard of aggressive antibiotic treatments may not always be the best answer, a decade-long study led by researchers at the University of Michigan has found.

Traditionally, bacteria-blasting antibiotics are used to suppress infection in CF patients' lungs to the lowest level possible, but maintaining a diversity of bacterial communities may help some patients stay healthy longer, says the study's senior author, John J. LiPuma, M.D.

The findings appear today in the .

"The has been that as patients with CF age and become sicker, as their progresses, more and more bacteria move in," says LiPuma, the James L. Wilson, M.D., Research Professor of Pediatrics and at the U-M Medical School. "But our study – which was the first to examine the bacterial communities in CF patients' lungs over a long period of time – indicates that's not what happens."

Instead, aggressive use of antibiotics – rather than a patient's age or disease progression – is responsible for lowering the diversity of bacteria, leading to infections that become increasingly hard to treat. A diverse community of bacteria may encourage competition that keeps the most virulent strains in check, the researchers found.

"What we normally do is essentially carpet bombing with antibiotics," continues LiPuma, who is also an associate chair of the pediatrics department at U-M. "However, what we found is that over time this ultimately helps treatment-resistant bacteria by getting rid of their competition."

LiPuma says the results may mark a first step toward developing new therapeutic approaches, such as more narrowly tailored use of or even a probiotic approach.

Cystic fibrosis is a chronic, life-threatening disease that leaves one vulnerable to repeated, ever-more-serious infections. It causes the body to produce thick, sticky mucus that clogs the lungs and provides the perfect breeding ground for bacteria. CF, which affects 30,000 people in the United States, is usually detected in early childhood and thanks to medical advances in recent decades, patients often survive into their 30s and 40s.

Even as bacterial diversity declines over time, the researchers found the overall level or "load" of bacteria remains fairly constant – meaning that as diversity declines, a small number of organisms multiply to take the place of those that have been destroyed.

Previous studies have collected samples from individual patients at a single point in time, which makes it difficult to examine relationships between the progression of the disease, and other variables, LiPuma explains. This study examined the bacteria from six patients collected over a period of eight to nine years. Three patients had a relatively stable type of the disease and three had the more typical, faster progressing form. DNA analysis was conducted on bacteria in 126 sputum samples.

The researchers were also surprised that exacerbations couldn't be linked to any specific changes in . Additional research is underway to look for more subtle signals that may precede or accompany flare ups, says LiPuma, who is also a professor of epidemiology at the U-M School of Public Health.

"Increasing our understanding of the relationship between bacteria in the lung and the progression of is critical to developing new treatments and prolonging patients' lives," he notes.

Explore further: Study shows new medication effectively treats underlying cause of cystic fibrosis

More information: "Decade-long bacterial community dynamics in cystic fibrosis airways," Proceedings of the National Academy of Sciences, March 26, 2012.

Related Stories

Study shows new medication effectively treats underlying cause of cystic fibrosis

November 2, 2011
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients ...

Recommended for you

Make way for hemoglobin

August 18, 2017
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is ...

Two-step process leads to cell immortalization and cancer

August 17, 2017
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally ...

New Pathology Atlas maps genes in cancer to accelerate progress in personalized medicine

August 17, 2017
A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns ...

Female mouse embryos actively remove male reproductive systems

August 17, 2017
A protein called COUP-TFII determines whether a mouse embryo develops a male reproductive tract, according to researchers at the National Institutes of Health and their colleagues at Baylor College of Medicine, Houston. The ...

New technique overcomes genetic cause of infertility

August 17, 2017
Scientists have created healthy offspring from genetically infertile male mice, offering a potential new approach to tackling a common genetic cause of human infertility.

Inhibiting a protein found to reduce progression of Alzheimer's and ALS in mice

August 17, 2017
(Medical Xpress)—A team of researchers with Genetech Inc. and universities in Hamburg and San Francisco has found that inhibiting the creation of a protein leads to a reduction in the progression of Alzheimer's disease ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Morin Brison
not rated yet Mar 27, 2012

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.